Blood Type and Susceptibility of SARS-Cov 2 Infection

Main Article Content

M. Nagervadze
L. Akhvlediani
T. Phutkaradze
M. Sikharulidze
M. Koridze
R. Khukhunaishvili


Introduction. It has been established by various authors that the frequency of distribution of ABO group antigens is directly related to the epidemic, infectious diseases such as plague, cholera, and measles. Epidemics and pandemics alter the genegeography characteristic of blood groups.

Material and methods. We study a total of 447 blood samples, 333 (age range 8-87 years) of which belonged to an infected and post-infected patient with SARS-Cov 2. A healthy control group of 114 individuals was also used for the study. The materials were taken from Kobuleti Central Hospital "Beaumonde" Clinical Laboratory (Adjara Region, Georgia republic, South Caucasus). The study also included volunteers who were infected with SARS-Cov 2 and recovered. Materials were collected in the 28/01/2021- 30/04/2021time interval.

All blood samples were processed on the basis of the Immunogenetics laboratory of the Biology Department of Batumi Shota Rustaveli State University (BSU) and Microbiology Laboratories of BAU Batumi International University (Georgia Republic). We used anti-A, anti-B, and anti-AB monoclonal antibodies for ABO blood typing.

Result. The ABO system blood group is unequally distributed in the control and Sarc-Cov2 infected patients groups. The unequal distribution mainly refers to the O (I) and A (II) groups. The A (II) group is found in the infected patient's group in almost 13.7% more cases than in the healthy control group. O (I) phenotypic group is 16.4% less present in patients compared to the healthy control group (The χ2 is 9.134. P-value - .027561). The results are significant at p <.05.

Conclusion. In the current study, compared with the ABO blood group distribution of healthy controls in the Adjara region (Georgia republic), the SARS‐CoV‐2  infection rate was higher in the A blood group. O (I)  blood group show low susceptibility to SARS‐CoV‐2 infection. Our results are in agreement with other scientific studies. We think that the results of the study will make a certain contribution to the meta-analysis of this issue.

Article Details

How to Cite
M. Nagervadze, L. Akhvlediani, T. Phutkaradze, M. Sikharulidze, M. Koridze, & R. Khukhunaishvili. (2022). Blood Type and Susceptibility of SARS-Cov 2 Infection. Journal of Coastal Life Medicine, 10(3), 46–56. Retrieved from


D. D. FARHUD and M. ZARIF YEGANEH, “A Brief History of Human Blood Groups,” Iran. J. Public Health, vol. 42, no. 1, pp. 1–6, Jan. 2013.

G. Daniels, “Functional aspects of red cell antigens,” Blood Rev., vol. 13, no. 1, pp. 14–35, Mar. 1999, doi: 10.1016/S0268-960X(99)90020-6.

D. R. Ewald and S. C. J. Sumner, “Blood type biochemistry and human disease: Blood type biochemistry and human disease,” Wiley Interdiscip. Rev. Syst. Biol. Med., vol. 8, no. 6, pp. 517–535, Nov. 2016, doi: 10.1002/wsbm.1355.

J. P. Cartron and Y. Colin, “Structural and functional diversity of blood group antigens,” Transfus. Clin. Biol., vol. 8, no. 3, pp. 163–199, Jun. 2001, doi: 10.1016/S1246-7820(01)00142-2.

G. A. Denomme, “Molecular basis of blood group expression,” Transfus. Apher. Sci., vol. 44, no. 1, pp. 53–63, Feb. 2011, doi: 10.1016/j.transci.2010.12.010.

S. B. Abegaz, “Human ABO Blood Groups and Their Associations with Different Diseases,” BioMed Res. Int., vol. 2021, pp. 1–9, Jan. 2021, doi: 10.155/2021/6629060.

G. Garratty, “Relationship of blood groups to disease: do blood group antigens have a biological role?,” Rev Med Inst Mex Seguro Soc, p. 10.

“Blood Group, Immunity, and Risk of Infection with Vibrio cholerae in an Area of Endemicity | Infection and Immunity.” (accessed Sep. 03, 2021).

David. J. Anstee, “The relationship between blood groups and disease,” Blood, vol. 115, no. 23, pp. 4635–4643, Jun. 2010, doi: 10.1182/blood-2010-01-261859.

L. Cooling, “Blood Groups in Infection and Host Susceptibility,” Clin. Microbiol. Rev., vol. 28, no. 3, pp. 801–870, Jul. 2015, doi: 10.1128/CMR.00109-14.

“Definition of SARS-CoV-2 - NCI Dictionary of Cancer Terms - National Cancer Institute,” Feb. 02, 2011. (accessed Sep. 03, 2021).

H. A. Rothan and S. N. Byrareddy, “The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak,” J. Autoimmun., vol. 109, p. 102433, May 2020, doi: 10.1016/j.jaut.2020.102433.

D.-G. Ahn et al., “Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19),” J. Microbiol. Biotechnol., vol. 30, no. 3, pp. 313–324, Mar. 2020, doi: 10.4014/jmb.2003.03011.

Y. A. Helmy, M. Fawzy, A. Elaswad, A. Sobieh, S. P. Kenney, and A. A. Shehata, “The COVID-19 Pandemic: A Comprehensive Review of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and Control,” J. Clin. Med., vol. 9, no. 4, p. 1225, Apr. 2020, doi: 10.3390/jcm9041225.

C.-C. Lai, T.-P. Shih, W.-C. Ko, H.-J. Tang, and P.-R. Hsueh, “Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges,” Int. J. Antimicrob. Agents, vol. 55, no. 3, p. 105924, Mar. 2020, doi: 10.1016/j.ijantimicag.2020.105924.

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses, “The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2,” Nat. Microbiol., vol. 5, no. 4, pp. 536–544, Apr. 2020, doi: 10.1038/s41564-020-0695-z.

S. de Lusignan et al., “Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study,” Lancet Infect. Dis., vol. 20, no. 9, pp. 1034–1042, Sep. 2020, doi: 10.1016/S1473-3099(20)30371-6.

M. Pareek et al., “Ethnicity and COVID-19: an urgent public health research priority,” The Lancet, vol. 395, no. 10234, pp. 1421–1422, May 2020, doi: 10.1016/S0140-6736(20)30922-3.

“Association of Sociodemographic Factors and Blood Group Type With Risk of COVID-19 in a US Population | Infectious Diseases | JAMA Network Open | JAMA Network.” (accessed Sep. 03, 2021).

F. Zhou et al., “Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study,” The Lancet, vol. 395, no. 10229, pp. 1054–1062, Mar. 2020, doi: 10.1016/S0140-6736(20)30566-3.

J. W. M. Chan, “Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS),” Thorax, vol. 58, no. 8, pp. 686–689, Aug. 2003, doi: 10.1136/thorax.58.8.686.

D. Yanardag Acik and M. Bankir, “Relationship of SARS-CoV-2 Pandemic with Blood Groups,” Transfus. Med. Hemotherapy, vol. 48, no. 3, pp. 161–167, 2021, doi: 10.1159/000515609.

J. Li, X. Wang, J. Chen, Y. Cai, A. Deng, and M. Yang, “Association between ABO blood groups and risk of SARS‐CoV‐2 pneumonia,” Br. J. Haematol., vol. 190, no. 1, pp. 24–27, Jul. 2020, doi: 10.1111/bjh.16797.

The Severe Covid-19 GWAS Group, “Genomewide Association Study of Severe Covid-19 with Respiratory Failure,” N. Engl. J. Med., vol. 383, no. 16, pp. 1522–1534, Oct. 2020, doi: 10.1056/NEJMoa2020283.

M. B. Barnkob et al., “Reduced prevalence of SARS-CoV-2 infection in ABO blood group O,” Blood Adv., vol. 4, no. 20, pp. 4990–4993, Oct. 2020, doi: 10.1182/bloodadvances.2020002657.

R. L. Hoiland et al., “The association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19,” Blood Adv., vol. 4, no. 20, pp. 4981–4989, Oct. 2020, doi: 10.1182/bloodadvances.2020002623.

N. A. El-Shitany et al., “The Impact of ABO Blood Grouping on COVID-19 Vulnerability and Seriousness: A Retrospective Cross-Sectional Controlled Study among the Arab Community,” Int. J. Environ. Res. Public. Health, vol. 18, no. 1, p. 276, Jan. 2021, doi: 10.3390/ijerph18010276.

C. A. Latz et al., “Blood type and outcomes in patients with COVID-19,” Ann. Hematol., vol. 99, no. 9, pp. 2113–2118, Sep. 2020, doi: 10.1007/s00277-020-04169-1.

M. O’Driscoll et al., “Age-specific mortality and immunity patterns of SARS-CoV-2,” Nature, vol. 590, no. 7844, pp. 140–145, Feb. 2021, doi: 10.1038/s41586-020-2918-0.

H. S. Yang et al., “Association of Age With SARS-CoV-2 Antibody Response,” JAMA Netw. Open, vol. 4, no. 3, p. e214302, Mar. 2021, doi: 10.1001/jamanetworkopen.2021.4302.

J. F. Ludvigsson, “Systematic review of COVID‐19 in children shows milder cases and a better prognosis than adults,” Acta Paediatr., vol. 109, no. 6, pp. 1088–1095, Jun. 2020, doi: 10.1111/apa.15270.

V. Bajaj, N. Gadi, A. P. Spihlman, S. C. Wu, C. H. Choi, and V. R. Moulton, “Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections?,” Front. Physiol., vol. 11, p. 571416, Jan. 2021, doi: 10.3389/fphys.2020.571416.

S. Albánez et al., “Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms,” J. Thromb. Haemost., vol. 14, no. 5, pp. 953–963, May 2016, doi: 10.1111/jth.13294.

A. de Paula Sabino et al., “ABO blood group polymorphisms and risk for ischemic stroke and peripheral arterial disease,” Mol. Biol. Rep., vol. 41, no. 3, pp. 1771–1777, Mar. 2014, doi: 10.1007/s11033-014-3026-8.

“Геногеографияэритроцитарных (ABO, Rh-Hr, Kell, MN) антигеновсрединаселенияАджарскойАР (Грузия) | Статьявсборникемеждународнойнаучнойконференции.” (accessed Jun. 27, 2021).

M. Nagervadze et al., “ABO system combination with Rh, Kell and MN group in Georgian blood donors,” Am. J. Blood Res., vol. 11, no. 2, pp. 132–139, Apr. 2021.

J. Li, X. Wang, J. Chen, Y. Cai, A. Deng, and M. Yang, “Association between ABO blood groups and risk of SARS‐CoV‐2 pneumonia,” Br. J. Haematol., vol. 190, no. 1, pp. 24–27, Jul. 2020, doi: 10.1111/bjh.16797.

R. Mahmud et al., “Association of ABO blood groups with presentation and outcomes of confirmed SARS CoV-2 infection: A prospective study in the largest COVID-19 dedicated hospital in Bangladesh,” PLOS ONE, vol. 16, no. 4, p. e0249252, Apr. 2021, doi: 10.1371/journal.pone.0249252.

P. Arend, “Why blood group A individuals are at risk whereas blood group O individuals are protected from SARS-CoV-2 (COVID-19) infection: A hypothesis regarding how the virus invades the human body via ABO(H) blood group-determining carbohydrates,” Immunobiology, vol. 226, no. 3, p. 152027, May 2021, doi: 10.1016/j.imbio.2020.152027.

R. Goel et al., “ABO blood group and COVID‐19: a review on behalf of the ISBT COVID‐19 working group,” Vox Sang., p. vox.13076, Feb. 2021, doi: 10.1111/vox.13076.

M. Miotto, L. Di Rienzo, G. Gosti, E. Milanetti, and G. Ruocco, “Does blood type affect the COVID-19 infection pattern?,” PLOS ONE, vol. 16, no. 5, p. e0251535, May 2021, doi: 10.1371/journal.pone.0251535.

“Titers of ABO antibodies in group O blood donors.” (accessed Sep. 07, 2021).

shaghayegh Arabi, M. Moghadam, V. Maleki, A. A. Pourfatholah, and A. Aghaie, “Different Immune Responses in Dangerous O Blood Donors,” Iran. J. Pathol., vol. 15, no. 1, pp. 34–40, Jan. 2020, doi: 10.30699/ijp.2019.104673.2075.

S.-C. Wu et al., “The SARS-CoV-2 receptor-binding domain preferentially recognizes blood group A,” Blood Adv., vol. 5, no. 5, pp. 1305–1309, Mar. 2021, doi: 10.1182/bloodadvances.2020003259.

P. V. Jenkins and J. S. O?Donnell, “ABO blood group determines plasma von Willebrand factor levels: a biologic function after all?,” Transfusion (Paris), vol. 46, no. 10, pp. 1836–1844, Oct. 2006, doi: 10.1111/j.1537-2995.2006.00975.x.

M. Franchini et al., “ABO blood group and risk of coronary artery disease,” J. Thromb. Thrombolysis, vol. 36, no. 3, pp. 286–287, Oct. 2013, doi: 10.1007/s11239-012-0836-1.

U. E. Nydegger, W. A. Wuillemin, F. Julmy, B. J. Meyer, and T. P. Carrel, “Association of ABO histo-blood group B allele with myocardial infarction: Histo-blood group B allele associated with myocardial infarction,” Eur. J. Immunogenet., vol. 30, no. 3, pp. 201–206, Jun. 2003, doi: 10.1046/j.1365-2370.2003.00390.x.